The specificity of ACSL4 action on mTOR signaling was assessed by the specific inhibition of ACSL4 expression by doxycycline in the MCF-7 Tet-Off/ACSL4 model, by the expression of ACSL4 in the non-aggressive T47D breast cancer cell line and by the downregulation of ACSL4 expression in the very aggressive MDA-MB-231 breast cancer cells that constitutively expresses ACSL4. Here, MTOR is linked to breast carcinoma.